CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!
Fremont, Sunny California
Joined February 2010
- Tweets226
- Following86
- Followers165
- Likes397
Dinesh V. Patel, PhD retweeted
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet business-news-today.com/take… $TAK $PTGX #Takeda #ProtagonistTherapeutics #MIMRYLO #Rusfertide #PolycythemiaVera #Hematology #FDA
Dinesh V. Patel, PhD retweeted
Congrats dad (@ProtagonistCEO)!
I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.
Dinesh V. Patel, PhD retweeted
Happy holidays from Protagonist Therapeutics! Warmest wishes to you and yours this holiday season ❄️
Dinesh V. Patel, PhD retweeted
It’s #WorldPsoriasisDay, and this year's theme aims to put a spotlight on Psoriatic Disease and Comorbidities. Psoriasis is a journey of visible and invisible challenges that not only impacts the skin, but also overall health and well-being.
At Protagonist Therapeutics, we’re proud to join @NPF and the global psoriasis community to raise awareness, advance research, and work toward a future with better care for the 125 million people around the globe living with psoriasis.
Dinesh V. Patel, PhD retweeted
Our EVP of Business Development, Carter King, will join a panel on 'Deal Stories – Wins, Misses, and What We'd Do Differently' tomorrow from 9:30-10:15 AM at #FierceBiotechWeek.
More details here: fiercebiotechweek.com/event/…
ALT Protagonist Therapeutics Fierce Biotech Week Headshot of Protagonist's Executive Vice President of Business Development, Carter King PANEL Deal Stories - Wins, Misses, and What We'd Do Differently Thu, Oct 9 9:30 AM - 10:15 AM
Dinesh V. Patel, PhD retweeted
For more than 20 years, @CALifesciences has celebrated individuals and organizations who are making exceptional contributions to the life sciences industry.
There is one more day for the Pantheon 2025 Awards voting, and our Protagonist team needs your help to win!
Vote for us in the Biopharma Product of the year category today: share.hsforms.com/1FMf9fZg4Q…
ALT California Life Sciences 2025 Pantheon Award Biopharma Product of the Year Vote for us! Protagonist Therapeutics CALIFORNIA LIFE SCIENCES PANTHEON Awards 2025
Dinesh V. Patel, PhD retweeted
Whether you joined us in-person or virtually, we’d like to thank everyone who took part in our investor event to learn about Protagonist’s ongoing research to address unmet medical needs for polycythemia vera (PV) patients. (1/2)
Dinesh V. Patel, PhD retweeted
Many thanks to Dr. Andrew @KuykendallMd from Moffitt Cancer Center and Dr. Joseph Scandura from Weill Cornell Medicine for sharing your expertise and leading an insightful discussion on current and future treatment options for PV. (2/2)
Dinesh V. Patel, PhD retweeted
One year ago today, the @NEJM published pivotal data from the Phase 2b FRONTIER 1 trial, evaluating an oral peptide designed to selectively block IL23R in adults living with moderate-to-severe plaque #psoriasis (PsO).
See a video summary of the findings:
Dinesh V. Patel, PhD retweeted
On Intl. Day of Women & Girls in Science we celebrate the women in STEM inspiring the next generation of innovators!
We also give a shoutout of appreciation to the impactful Protagonist team members, collaborators, and researchers supporting our mission to improve patient lives.
Dinesh V. Patel, PhD retweeted
On Feb. 6 at 10:30am ET, KOLs Andrew @KuykendallMd
and Joseph Michael Scandura, MD, PhD, will discuss the unmet medical need and current treatment landscape for patients with polycythemia vera (PV).
Register for the in-person and virtual event here: bit.ly/40tSC47
ALT Protagonist Therapeutics logo KOL INSIGHTS ON POLYCYTHEMIA VERA (PV) AND THE HEPCIDIN MIMETIC RUSFERTIDE Midtown, New York and Live Webcast Featuring Andrew Kuykendall, MD (Moffitt Cancer Center) and Joseph M. Scandura, MD, PhD (Weill Cornell Medicine) THURSDAY, FEBRUARY 6, 2025 | 10:30 AM ET NASDAQ: PTGX LifeSci Events logo
Dinesh V. Patel, PhD retweeted
In BioCentury’s latest Clinical Report: New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data; CRISPR, RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte buff.ly/4fTSr8y
Dinesh V. Patel, PhD retweeted
𝐅𝐫𝐨𝐦 𝐉𝐚𝐩𝐚𝐧: @TakedaPharma's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets. $TAK
Full video: biotechtv.com/post/takeda-ch…
Dinesh V. Patel, PhD retweeted
Today we announced that final data from the Phase 2 REVIVE study in polycythemia vera will be the focus of a poster presentation at the 66th Annual @ASH_hematology Meeting.
See more details in our press release. #ASH24
Dinesh V. Patel, PhD retweeted
Today, we reported financial results for the third quarter 2024 and provided a corporate update.
See the full press release here:
Dinesh V. Patel, PhD retweeted
Each year, ~20,000 Americans are diagnosed with an MPN, a group of rare blood cancers that start in the bone marrow where blood cells are made.
For #MPNAwarenessDay and #BloodCancerAwarenessMonth, see the symptoms and what to expect after a diagnosis: self.com/story/rare-blood-ca…
Dinesh V. Patel, PhD retweeted
According to the World Psoriasis Day Consortium, 125 million people worldwide - 2-3% of the population - have psoriasis.
For #PsoriasisAwarenessMonth, get more facts on the @NPF website: psoriasis.org/psoriasis-stat…
ALT AUGUST IS PSORIASIS AWARENESS MONTH
Dinesh V. Patel, PhD retweeted
Today, we reported financial results for the second quarter 2024 and provided a corporate update.
See more in our press release:
Dinesh V. Patel, PhD retweeted
Today we announced the publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal @SciReports. In the study, in human cells, JNJ-2113 potently and selectively inhibited proximal IL-23 signaling without impacting IL-12 signaling. nature.com/articles/s41598-0… (1/3)